According to Sionna Therapeutics, SION stock plunged roughly 92% on Monday after the biotech firm's experimental cystic fibrosis drug SION-719 failed to meet its mid-stage trial goals. The drug, tested as an add-on therapy to Vertex's Trikafta in 15 cystic fibrosis patients, barely lowered sweat chloride levels—a key marker of protein function improvement—showing only a minor difference versus placebo that was not statistically significant. The company abandoned plans to advance SION-719 in this combination role and said it will preserve capital while assessing its path forward, ending the second quarter with approximately $268 million in cash. Vertex's stock rose 7% following the news. Stifel downgraded Sionna to Hold from Buy, lowering its price target to $7 from $55.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate US. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate US does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments involve high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
